Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model

Journal of Pediatric Hematology/Oncology

Volumn 21, Issue 1, 1999, Pages 26-30

  Berg, Stacey L ^a,d   Reid, Joel ^c   Godwin, Karen ^b   Murry, Daryl J ^a   Poplack, David G ^a   Balis, Frank M ^b   Ames, Matthew M ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MAYO CLINIC   (United States)

^d TEXAS CHILDREN S CANCER CENTER   (United States)

Author keywords

Cerebrospinal fluid; Daunorubicin; Idarubicin; Metabolites; Pharmacokinetics

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; DAUNORUBICINOL; IDARUBICIN; IDARUBICINOL;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CEREBROSPINAL FLUID EXAMINATION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; MALE; MODEL; NONHUMAN; PLASMA CLEARANCE; PRIMATE; PRIORITY JOURNAL; RHESUS MONKEY;

EID: 0033067351     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199901000-00006     Document Type: Article

References (17)

1. Arcamone F, Bernardi L, Giardino P, et al. Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7, 9-diepidaunorubicine, and their β anomers. Cancer Treatment Rep 1976;60:829-34.
2. Robert J: Clinical pharmocokinetics of idarubicin. Clin Pharmacokinet 1993;24:275-88.
3. Kuffel MJ, Ames MM. Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metabolites in human MDR1 transfected NIH-3T3 Cells. Cancer Chemother Pharmacol 1995;36: 223-26.
4. Ross DD, Doyle LA, Yang W, et al. Susceptibility of idarubicin, doxorubicin and their C-13 alcohol metabolites to transport-mediated multidrug resistence. Biochem Pharmacol 1995;50:1673-83.
5. Reid JM, W. Pendergrass T, Krailo MD, et al. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Children's Cancer Study Group report. Cancer Res 1990;50:6525-8.
6. Guide for the care and use of laboratory animals. Department of Health, Education and Welfare Publication (NIH) 84-23, Revised. 1988.
7. McCully C, Baus F, Bacher J, et al. A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab Animal Sci 1990;40:522-5.
8. Knott G: MLAB-a mathematical modeling tool. Computer Programs Biomed 1979;10:271-280.
9. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-175.
10. Perrier D, Mayersohn M: Noncompartmental determination of the steady-state volume of distribution for any mode of administration. J Pharm Sci 1982;71:373-373.
11. Myers C, Chabner B. Anthracyclines. In: Cancer Chemotherapy: Principles and Practice. Chabner B, Collins J, (ed). Philadelphia: JB Lippincott, 1990;356-81.
12. Greene R, Collins J, Jenkins J. et al. Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Res 1983;43: 3417-21.
13. Kuffel M, Reid J, Ames M. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother Pharmacol 1992;30:51-57.
14. Greig N: Optimizing drug delivery to brain tumors. Cancer Treat Rev 1987;14:1-28.
15. Kock-Weser J, Sellars E: Binding of drugs to serum albumin. N Engl J Med 1976;294:311-6.
16. Hollingshead LM, Faulds D. Idarubicin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 1991;42:690-719.
17. Blaney S, Poplack D. Intrathecal Chemotherapy. In: Principes of Antineoptastic Drug Development and Pharmacology. Schilsky R, Milano G, Ratain M. (eds). New York: Marcel Dekker, 1996;641-60.